“Woah! It's like Spotify but for academic articles.”

Instant Access to Thousands of Journals for just $40/month

Public Perspectives About Pharmacogenetic Testing and Managing Ancillary Findings

Public Perspectives About Pharmacogenetic Testing and Managing Ancillary Findings Aims: Pharmacogenetic (PGx) tests are intended to improve therapeutic outcomes through predicting a patient's likelihood to respond to or experience an adverse effect from a specific treatment. In addition, PGx testing may also generate ancillary, or incidental, disease information unrelated to the purpose for which the test was ordered. To assess public attitudes toward PGx testing, ancillary disease risk information and related clinical issues, we conducted a series of focus groups. Results: Forty-five individuals recruited from Durham, NC, participated in four focus groups. Overall, participants were enthusiastic about PGx testing, though expressed concerns about privacy, confidentiality, and psychological harms associated with ancillary information. Focus group participants believed that physicians had a responsibility to disclose ancillary risk information, but were concerned about managing and coping with unexpected disease risk information. Conclusion: We find that participants welcomed the integration of PGx testing into therapeutic decision-making. Public concerns about PGx testing and ancillary information specifically centered on personal implications of learning such additional information, suggesting that patient–provider discussion of the benefits and risks of testing will be necessary until public familiarity with these tests increases. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Genetic Testing and Molecular Biomarkers Mary Ann Liebert

Public Perspectives About Pharmacogenetic Testing and Managing Ancillary Findings

Abstract

Aims: Pharmacogenetic (PGx) tests are intended to improve therapeutic outcomes through predicting a patient's likelihood to respond to or experience an adverse effect from a specific treatment. In addition, PGx testing may also generate ancillary, or incidental, disease information unrelated to the purpose for which the test was ordered. To assess public attitudes toward PGx testing, ancillary disease risk information and related clinical issues, we conducted a series of focus groups. Results: Forty-five individuals recruited from Durham, NC, participated in four focus groups. Overall, participants were enthusiastic about PGx testing, though expressed concerns about privacy, confidentiality, and psychological harms associated with ancillary information. Focus group participants believed that physicians had a responsibility to disclose ancillary risk information, but were concerned about managing and coping with unexpected disease risk information. Conclusion: We find that participants welcomed the integration of PGx testing into therapeutic decision-making. Public concerns about PGx testing and ancillary information specifically centered on personal implications of learning such additional information, suggesting that patient–provider discussion of the benefits and risks of testing will be necessary until public familiarity with these tests increases.
Loading next page...
 
/lp/mary-ann-liebert/public-perspectives-about-pharmacogenetic-testing-and-managing-Kutq2IPqXA

Sorry, we don't have permission to share this article on DeepDyve,
but here are related articles that you can start reading right now: